Plné znění - 2/2008 Sb. m. s.

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 16. xxxxxxxxx 2007 bylo xxxxxxxxxx xxxxxxxxx UNESCO, xxxxxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx sportu¹⁾, xxxxxxxx schválení xxxxxx xxxxx Přílohy I - Xxxxxxx xxxxxxxxxx xxxxx x metod dopingu.

Xxxxxxx I vstoupila x platnost v xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2008 x xxxxx xxxx vstoupila x xxxxxxxx x xxx Xxxxxx republiku. Dnem xxxxxx Xxxxxxx I x xxxxxxxx přestává xxxxxx Příloha X Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx xx znění xxx xxx 2007, xxxxxxxxx xxx č. 59/2007 Xx. x. s.

Xxxxxxxx znění Xxxxxxx X a xxxx xxxxxxx do xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.

X1. ANABOLICKÉ XXXXX

Xxxxxxxxxx látky jsou xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX STEROIDY (AAS):

x. Exogenní * XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-androst-1-en-3,17-dion); xxxxxxxxx (19-xxxxxxxxxxxxxxxx); bolasteron; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); dehydrochlormethyltestosteron (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-xxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); kalusteron; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; methandriol; xxxxxxxxxx (2α, 17α-xxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); norboleton; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; prostanozol ([3,2-x]xxxxxxx-5α-xxxxxxxxxxxxxx-17β-xxxxxxxxxxxxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-homo-pregna-4,9,11-trien-17β-ol-3-on); xxxxxxxxx x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

b. Xxxxxxxxx ** AAS:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX), xxxxxxxxxxx x následující xxxxxxxxxx x xxxxxxx:

5α-xxxxxxxxx-3α,17α-xxxx xxxxxxx-5-xx-3β,17α-xxxx

5α-xxxxxxxxx-3α,17β-xxxx 4-xxxxxxxxxxxxx (androst-4-en-3β,17β-diol)

5α-xxxxxxxxx-3β,17α-xxxx 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)

5α-androstan-3β,17β-diol epi-dihydrotestosteron

xxxxxxx-4-xx-3α,17α-xxxx 3α-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-4-xx-3α,17β-xxxx 3β-xxxxxxx-5αxxxxxxxxx-17-xx

androst-5-en-3β,17α-diol 19-norandrosteron

xxxxxxx-5-xx-3α,17α-xxxx 19-xxxxxxxxxxxxxxxxx

xxxxxxx-5-xx-3α,17β-xxxx

X xxxxxxxxx, xxx může xxxx xxxxxxxxxx androgenní xxxxxxxxxx steroid xxxxxxxxx, xxxx xx xxx xx xx, xx Xxxxxx obsahuje tuto Xxxxxxxxx xxxxx x xxxx xxxxxx xxxxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxx se xxxxxxxxxxx Xxxxxxxx xxxxx xxxx xxxxxx metabolitů nebo xxxxxxxxxxx a/nebo xxxx xx xxxxxxxx xxxx xxxxxxxxx xxxxx xx Xxxxxx Xxxxxxxxx významně xxxxxxxxx xx xxxxxxx xxxxxx, xxxxx xx xxxxxxxx xxxxxxxxx x xxxx tak, xx xxxxxxxxxx normální endogenní xxxxxxxx. Nebude se xxx xx xx, xx Xxxxxx obsahuje Xxxxxxxxx xxxxx v xxxxxxx xxxxxxx, xxxxx Xxxxxxxxx prokáže, xx xx koncentrace Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx nebo xxxxxxxxxx x/xxxx příslušný xxxxx xx Xxxxxx Sportovce xxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxxxxx stavem.

Xxxx xx xxx za xx, že Xxxxxx Xxxxxxxxx xxxxxxxx Zakázanou xxxxx a laboratoř xxxxxxx Pozitivní xxxxxxxxxxx xxxxx ve všech xxxxxxxxx a při xxxxxxxxx xxxxxxxxxxx, xxxxx xxx podle xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) prokázat, xx xx Xxxxxxxx xxxxx xxxxxxxxxx xxxxxx. X xxxxxxx xxxxxxx xxxx xxxxx xxxxxxxx xxxxx xxxxxxx.

Když se xxxxxxx xxxxxxxx analýzy xxxxxxxx xxxxxxxxxxx od xxxxxxx xxxxxx, které xx normálně xxxxxxxxx x xxxx x xxxxx spolehlivá xxxxxxxxxx xxxxxx (xxxx. IRMS) xxxxxxxxxxx exogenní xxxxx Xxxxxxxx xxxxx, xxx xxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx, xxxx xxxx. xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxxx xxxx xxxxxxxxx xxxxxxxxx poměr X/X xxxxx než xxxxx (4) xx xxxxx (1) x xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (např. XXXX) xxxxxxxxxxx exogenní původ xxxxx, xxxxxxx xxxxxxxxx Xxxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxx testů xxxx xxxxxxxxxx xxxxxxxxxx testů.

Xx-xx vyžadováno xxxxxx xxxxx šetření, pak xxxxxxxx xxxx laboratoří xxxxxx xxxx neobvyklý x xx xxxx xxxxxxxxx. Pokud laboratoř xxxxxxx, xx xxxxxxx xxxxxxxxxx analytické xxxxxx (xxxx. IRMS) xxxxxxxx xxxxx Xxxxxxxx xxxxx, xxxx nutné xxxxxxxx xxxxx xxxxxxx, a xxxx xx xxx xx xx, xx Xxxxxx obsahuje Xxxxxxxxx xxxxx. Xxxxx xxxxxx xxxxxxx xxxxxxxxxx analytická xxxxxx (např. IRMS) x nejsou x xxxxxxxxx xxxxxxxxx 3 xxxxxxxxx xxxxx, xxxx xxxxxxx xxxxxxxxxxxxxx profil Xxxxxxxxx xxx, xx xxxx xxxxxxxxxx Xxxxxxxxxxxxxx xxxxxxxxxx v xxxxxxxxxxxxx 3 xxxxxxxx třikrát xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxx, který xxxxxxxxxx tuto longitudinální xxxxxx, bude hlášen xxxx xxxxxxxxx. Pokud xxxxxxxxxxxxxx profil Xxxxxxxxx, xxxxxxxx xxxxxxxxxx xxxxx, xxxx fyziologicky xxxxxxxx, xxxx se pak xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx.

V xxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx být x xxxx trvale xxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx velice xxxxxx xxxxxxxxxxxxx (xx/xx). Xxxxx xxxxxxxxx xxxxxx xxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (např. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx Xxxxxxxx xxxxx, xxxx xxx xxxxxxxxx xxxxx xxxxxxx provedením xxxxxxxxxx xxxxx (xxxxxxxxxx xxxxx).

Xxxxx laboratoř nahlásila Xxxxxxxxx xxxxxxxxxxx nález 19-xxxxxxxxxxxxxxx, bude xx xx xxxxxxxxx xx xxxxxxx a xxxxxxxxxxx xxxxx xxxxxxxxxx xxxxxx Xxxxxxxx látky. V xxxxxxx xxxxxxx xxxx xxxxx provádět další xxxxxxx.

X případě, xx Xxxxxxxxx nebude xxxxxxxxxxxxx xxx xxxxxxx xxxxxxxxx, xxxx xx xxx za xx, xx Xxxxxx Xxxxxxxxx xxxxxxxx Zakázanou xxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, zilpaterol, ale xx x xxxxxxxx xxxxx na ně.

S2. XXXXXXX X XXXXXXXX XXXXX

Následující xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx zakázány:

1. Erytropoetin (XXX);

2. Xxxxxxx xxxxxx (xXX), insulinu xxxxxxx xxxxxxx xxxxxxx (xxxx. XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (MGF);

3. Xxxxxxxxxxxxx (xxxx. XX, xXX), xxxxxxxx xxx x xxxx;

4. Xxxxxxxx;

5. Kortikotropiny

x xxxxx látky x podobnou xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.

Pokud Xxxxxxxxx nemůže xxxxxxxx, xx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx či xxxxxxxxxxxx xxxxxx, xxxx xx xxx xx xx, xx Xxxxxx xxxxxxxx Zakázanou látku (xxx xx xxxxxxx xxxx) v xxxxxxxxx, xxx koncentrace Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx xx xxxxxxxxxx x/xxxx xxxxxxxxx xxxxxx xx Xxxxxx Xxxxxxxxx xxxxxxx xxxxxxxx hodnoty xxxxxxxx xxxxxxxx x xxxx xxx, xx xxxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx.

Xxxxx laboratoř xxxxxxxxx, xx užití xxxxxxxxxx analytické xxxxxx, xx Xxxxxxxx xxxxx xx exogenního xxxxxx, xxxx se xxx xx xx, xx Xxxxxx obsahuje Xxxxxxxxx xxxxx x xxxx xxxxxxx Xxxxxxxxx laboratorní xxxxx.

X3. XXXX-2 AGONISTÉ

Xxxxxxx xxxx-2 agonisté xxxxxx xxxxxx D- x X-xxxxxxx xxxx xxxxxxxx.

Xxxxxxxx jsou xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx a xxxxxxxxxx, xxx xxxxx xx xxx xxxxxxxx xxxxx udělení xxxxxxxx xxxxxxxxxxxx xxxxxxx.

X xxxx xxxx xxxxxxx xxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx, xxxx nález xxxxxxxxxxx (xxxxx xxxx xxxxxxxxxx) vyšší xxx 1000 xxxxxxxxx x 1 xxxxxxxxx moči xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx neprokáže, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxx terapeutickým xxxxxxxx xxxxxxxxxxx x xxxxxxxx.

S4. ANTAGONISTÉ X XXXXXXXXXX XXXXXXX

Xxxxxxxxxxx skupiny xxxx xxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:

2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxx:

3. Xxxxxxx xxxxxxxxxxxxxx látky xxxxxxxxxx:

4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, xxx ne x omezením xxxxx xx ně.

X5. XXXXXXXXX A XXXXXXX XXXXXXXXX XXXXX

Xxxxxxxxx xxxxx xxxx xxxxxxxx. Xxxxxxxx:

Xxxxxxxxx*, xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx alfa-reduktázy (xxxx. xxxxxxxxxx, xxxxxxxxxx), xxxxxxxxxxxxxxx (xxxx. xxxxxxx, dextran, xxxxxxxxxxxxxxxxx) x xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Diuretika xxxxxxxx:

Acetazolamid, amilorid, xxxxxxxxx, furosemid, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, spironolakton, xxxxxxxx (např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), triamteren x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx).

* Xxxxxxxxxxxx xxxxxxx xxxx platná, xxxxx xxx Xxxxxxxxx xxxxxxxx diuretika ve xxxxxxx x xxxxxxxx xxxx podprahovou hladinou xxxx Xxxxxxxx látky (xxxxx).

X1. ZVYŠOVÁNÍ XXXXXXX XXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

M2. XXXXXXXX X FYZIKÁLNÍ MANIPULACE

M3. XXXXXX XXXXXX

Xxxxxxxxxxxxxx xxxxxxx xxxxx, xxxx, xxxxxxxx xxxxxxxx, xxxx xxxxxxxxxx exprese genů, xxxxx mají xxxxxxxxx xxxxxx sportovní xxxxx, xx xxxxxxxx.

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx (xxxxxx obou xxxxxx případných xxxxxxxxx (X- x X-) xxxxxxx) xxxx xxxxxxxx, x xxxxxxxx derivátů xxxxxxxxx v xxxxxxx xxxxxx xxxxxxxx xxxxx x xxxxxxxxxxx zahrnutých xx Monitorovacího programu xxx xxx 2008.

Xxxxxxxxxxx xxxxxxxx:

Xxxxxxxxx, xxxxxxxxx**, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxx****, xxxxxxxx, xxxxxxxxx, ethylamfetamin, famprofazon, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, fenkamfamin, fenkamin, xxxxxxxxxxx, fenprometamin, fenproporex, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, heptaminol, isomethepten, xxxxx***, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, levmetamfetamin, xxxxxxxxx, xxxxxxxxxxx, meklofenoxát, xxxxxxxxxxxx (X-), xxxxxxxxxxxx****, xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, pentetrazol, x-xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, strychnin, xxxxxxxxxxxxx x další látky x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxx xxxxxxxx x xxxxx oddíle xxxx xxxxxxxxxx xx specifickou xxxxx xxxxx, xxxxx Xxxxxxxxx xxxxxxx, xx xxxx všeobecná dostupnost x xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx antidopingových xxxxxxxx, xxxx xx u xxx xxxxx xxxxxxxxxxxxxxx, xx xxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxx xxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxxx, diamorfin(heroin), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx (xxxx. xxxxx, xxxxxxxxx) jsou xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, rektálně, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx. Xxxxxx xxxxx xxxxxxxx xxxxxxxxxxxxx xxxxxxx.

Xxxx xxxxxxx xxxxxxxx aplikace (xxxxxxxxxxxx, do okolí xxxxxx, xx okolí xxxxxx, epidurální, xx xxxx) x inhalační xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxx x xxxxxxxx xxxx xxxxxxxxx.

Xxxxxxx xxxxxxxxx xxxxxxxx xx potíže xxxxx (xxxxxx xxxxxxxxxxx/xxxxxxxxxx), ušní, xxxxx, xxxx, xxxxxx xxxxx xxxxxxx otvoru, xxxxxxxx xxx x xxxxx xxxxxx zakázané x xxxxxxxxxx xxxxxx xxxxx xxxxxxxxxxxx xxxxxxx.

P1. XXXXXXX

Alkohol (etanol) xx xxxxxxxx xxxxx Xxx xxxxxxx v xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx bude xxxxxxxx xxxxxxxx zkouškou x/xxxx xxxxxxxx xxxx. Prahová xxxxxxx pro porušení xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) je xxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxx.

∙ Xxxxxxxxxxxx xxxxx (FIA) (0.10 x/x)

∙ Xxxxxx (XXX) (0.10 x/x)

∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX) (0.20 g/l)

∙ Lukostřelba (XXXX, XXX) (0.10 g/l)

∙ Xxxxxxx xxxxxxx (XXXX) jen xxx xxxxxxxxxx xx střelbou (0.10 g/l)

∙ Xxxxxxxxxxx sport (XXX) (0.10 g/l)

∙ Xxxxx xxxxxxxxxx (XXX) (0.30 x/x)

∙ Kuželky (XXX) (0.10 x/x)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx určeno, xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx Xxx soutěži x následujících sportech.

∙ Xxxxxxxxxxxx xxxxx (XXX)

∙ Xxxxxxxx (XXXX)

∙ Xxxx (XXXX)

∙ Xxxxx (XXX)

∙ Xxxxxxx (XXX)

∙ Xxxxxxxxxx (XXX)

∙ Xxxxxxxx (XXXX) - "xxxxx xxxx" - xxx xxxxxxxxxxx

∙ Xxxxxxx (XXX)

∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX)

∙ Xxxxxxxxxxx (XXXX, IPC) (xxxxxxxx xxxx Xxxx xxxxxx)

∙ Lyžování (XXX) - xxxxx na xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x U-rampa, x xxxxxxxxx X-xxxxx x "big xxx"

∙ Xxxxxxx xxxxxxx (XXXX) - xxx xxxxxxxxxx se střelbou

∙ Xxxxxxxxxxx sport (XXX)

∙ Petanque x xxxxxxx xxxxxx (XXXX, IPC "xxxxx")

∙ Střelba (ISSF, XXX) (xxxxxxxx také Xxxx soutěž)

∙ Xxxxx xxxxxxxxxx (XXX)

∙ Xxxxx (XXXX)

Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, metipranolol, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx

"Xxxxxxxxxx xxxxx"* xxxx vyjmenovány xxxx:

∙ Xxxxxxx Xxxx-2 xxxxxxxx v xxxxxxxx, xxxxx xxxxxxxxxxx (volného xxxx xxxxxxxxxxx) xxx xxxxxxxx xxxxxx xxx 1000 ng/ml xxxx x clenbuterolu (xxxxxxx xx xxxxxxx S 1.2 Xxxxxxx xxxxxxxxxx xxxxx);

∙ Inhibitory xxxx-xxxxxxxxx, xxxxxxxxxx;

∙ Xxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxx, famprofazon, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, x-xxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, selegilin, xxxxxxxxxx, xxxxxxxxxxxxx x všechna xxxxxxx stimulancia xxxxxxxxx xxxxxxxx v oddíle X6, pro xxxxx Xxxxxxxxx xxxxxxx, že xxxxxxx podmínky xxxxxxx x oddíle X6;

∙ Xxxxxxxxxxx;

∙ Xxxxxxx Glukokortikosteroidy;

∙ Xxxxxxx;

∙ Xxxxxxx Xxxx-xxxxxxxxx.

*"V Xxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxxxx xxxxxxxx x xxxxxxx xxxxxxxxx přípravcích, nebo x nichž xx xxxxx pravděpodobnost, xx xxxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxx xxxxxxx." Xxxxxxxx antidopingového pravidla xxxxxxxxxx takovéto xxxxx xxxx xxxxxxxx xxxxxxx xxxxxx xx předpokladu, xx "...Xxxxxxxxx xxxx xxxxx prokázat, xx Xxxxxxx specifické xxxxx xxxxxx zamýšleno ke xxxxxxx xxxxxxxxxxx výkonu...".

Xxxxxx xxxxxxx č. 2/2008 Xx. x. x. xxxxx účinnosti xxxx 31.1.2008.

Xxxxxx xxxxxxx x. 2/2008 Sb. x. x. xxx xxxxxx xxxxxxx předpisem č. 8/2009 Sb. m. s. x účinností xx 7.2.2009.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x odkazech xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx.